Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=2431
{ "count": 24506, "next": "http://api.gregory-ms.com/articles/?format=api&page=2432", "previous": "http://api.gregory-ms.com/articles/?format=api&page=2430", "results": [ { "article_id": 214, "title": "Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment", "summary": "<div><p>Front Immunol. 2021 Feb 15;12:625465. doi: 10.3389/fimmu.2021.625465. eCollection 2021.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Here we report three cases of anti-myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) mimicking multiple sclerosis in which seropositivity for anti-MOG antibodies occurred during disease-modifying drug dimethyl fumarate (DMF) treatment. These patients developed relapses with anti-MOG antibody seroconversion after switching from fingolimod or steroid pulse therapy to DMF, which was associated with peripheral lymphocyte recovery. MOGAD is considered a humoral immune disease, and DMF reportedly enhances Th2-skewed humoral immune activity. Therefore, we suggest that DMF, but not fingolimod, may exacerbate humoral immune imbalance and enhance autoantibody production, leading to aggravation of MOGAD.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33659007/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33659007</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7917254/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7917254</a> | DOI:<a href=\"https://doi.org/10.3389/fimmu.2021.625465\">10.3389/fimmu.2021.625465</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33659007/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-02-15T00:00:00Z", "source": "PubMed", "publisher": "Frontiers Media SA", "container_title": "Frontiers in Immunology", "authors": [ { "author_id": 253862, "given_name": "Keita", "family_name": "Takahashi", "ORCID": null, "country": null }, { "author_id": 253865, "given_name": "Hideyuki", "family_name": "Takeuchi", "ORCID": null, "country": null }, { "author_id": 253860, "given_name": "Ryoko", "family_name": "Fukai", "ORCID": null, "country": null }, { "author_id": 253858, "given_name": "Haruko", "family_name": "Nakamura", "ORCID": null, "country": null }, { "author_id": 301108, "given_name": "Keisuke", "family_name": "Morihara", "ORCID": null, "country": null }, { "author_id": 301109, "given_name": "Yuichi", "family_name": "Higashiyama", "ORCID": null, "country": null }, { "author_id": 241744, "given_name": "Toshiyuki", "family_name": "Takahashi", "ORCID": null, "country": null }, { "author_id": 253846, "given_name": "Hiroshi", "family_name": "Doi", "ORCID": null, "country": null }, { "author_id": 165173, "given_name": "Fumiaki", "family_name": "Tanaka", "ORCID": "http://orcid.org/0000-0002-9961-2693", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Case Report", "Anti-MOG Antibody Seroconversion", "Dimethyl Fumarate Treatment" ], "doi": "10.3389/fimmu.2021.625465", "access": "open", "takeaways": " Patients developed relapses with anti-MOG antibody seroconversion after switching from fingolimod or steroid pulse therapy to DMF, which was associated with peripheral lymphocyte recovery . DMF reportedly enhances Th2-skewed humoral", "categories": [ { "category_id": 5, "category_description": "Tecfidera is a medicine used to treat multiple sclerosis (MS), a disease in which inflammation damages the protective insulation around nerves (demyelination) as well as the nerves themselves. It is used in adults and children from 13 years of age with a type of MS known as relapsing-remitting MS, where the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions).\r\n\r\nTecfidera contains the active substance dimethyl fumarate.\r\n\r\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera", "category_name": "Tecfidera", "category_slug": "tecfidera", "category_terms": [ "tecfidera", "dimethyl fumarate" ], "article_count": 162 } ] }, { "article_id": 203, "title": "Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "summary": "<div><p>Front Pharmacol. 2020 Nov 20;11:589146. doi: 10.3389/fphar.2020.589146. eCollection 2020.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><b>Background:</b> Ozanimod has been approved for use in the treatment of relapsing forms of multiple sclerosis by the United States FDA. As a novel, orally available sphingosine 1-phosphate receptor modulator, ozanimod selectively binds to S1P1 and S1P5 receptor with high affinity, minimizing safety concerns caused by S1P<sub>3</sub> receptor activation. <b>Methods:</b> e systematically searched PUBMED, EMBASE database, and Cochrane Library database to identify randomized controlled trials (RCTs) from inception to June 28, 2020. Trials were considered eligible if they 1) were randomized clinical trials (RCTs); 2) enrolled adult participants diagnosed with Relapsing-remitting MS; 3) compared ozanimod with placebo or any other approved DMDs that evaluated in phase III or phase II clinical trials; 4) enrolled over 100 participants; 5) provided any available information for predefined primary or secondary outcomes. <b>Results:</b> 2917 participants from three high-quality, multi-centered randomized clinical trials were pooled in our analysis. We found that using ozanimod was significantly associated with the reduction of the annualized relapse rate during the treatment period (RR, -0.10 [95% CI, -0.15, -0.06]). Also, the decreased number of gadolinium-enhancing lesions at the end of the trial was relative to the treatment of ozanimod (ozanimod, 0.29; control, 0.65; RR, -0.20 [95% CI, -0.34, -0.06]). Compared with patients in the control group, the number of new or enlarging T2 lesions over the treatment period decreased in patients treated with ozanimod (ozanimod, 1.82; control, 3.55; RR, -1.12 [95% CI, -1.52, -0.71]). As to the safety endpoints, patients in the ozanimod group reported a lower rate of adverse events (ozanimod, 66.03%; control, 77.07%; RR, 0.64 [95% CI, 0.43, 0.95]). Similar incidence of infection-related TEAEs was found across treatment groups (nasopharyngitis: ozanimod, 11.19%; control, 9.83%; RR, 1.10 [95% CI, 0.77-1.57]; urinary-tract infection: ozanimod, 3.81%; control, 2.97%; RR, 1.29 [95% CI, 0.83-2.00]). No case of macular edema was noted as well as second-degree, type 2, or third-degree atrioventricular block. As for the subgroup analysis, compared with 0.5 mg ozanimod, 1 mg ozanimod is related with a significant reduction of the annualized relapse rate during the treatment period (1 mg ozanimod, 0.18; 0.5 mg ozanimod, 0.24; RR, 0.05 [95% CI, 0.01, 0.09])and a decreased number of new or enlarging T2 lesions over the treatment period (1 mg ozanimod,1.58; 0.5 mg ozanimod, 2.05; RR, 0.49 [95% CI, 0.19, 0.79]). No significant difference in causing adverse events between 1 and 0.5 mg was found. <b>Conclusions:</b> Our meta-analysis found that, with favorable safety performance, the use of ozanimod as a treatment of relapsing-remitting multiple sclerosis in adults was associated with a significant reduction of the annualized relapse rate during the treatment period, decreased number of gadolinium-enhancing lesions at the end of the trial, and lowered number of new or enlarging T2 lesions over the treatment period. Ozanimod 1 mg outperformed 0.5 mg dose in efficacy without increasing the risk of adverse events.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33658933/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33658933</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7919188/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7919188</a> | DOI:<a href=\"https://doi.org/10.3389/fphar.2020.589146\">10.3389/fphar.2020.589146</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33658933/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2020-11-20T00:00:00Z", "source": "PubMed", "publisher": "Frontiers Media SA", "container_title": "Frontiers in Pharmacology", "authors": [ { "author_id": 308540, "given_name": "Yue", "family_name": "Sun", "ORCID": null, "country": null }, { "author_id": 308541, "given_name": "Yanbo", "family_name": "Yang", "ORCID": null, "country": null }, { "author_id": 272312, "given_name": "Zilan", "family_name": "Wang", "ORCID": null, "country": null }, { "author_id": 308542, "given_name": "Fan", "family_name": "Jiang", "ORCID": null, "country": null }, { "author_id": 272313, "given_name": "Zhouqing", "family_name": "Chen", "ORCID": null, "country": null }, { "author_id": 174967, "given_name": "Zhong", "family_name": "Wang", "ORCID": "http://orcid.org/0000-0002-7342-0845", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Ozanimod", "Treatment", "Relapsing-Remitting Multiple Sclerosis", "Adults", "A Systematic Review", "Meta-Analysis", "Randomized Controlled Trials" ], "doi": "10.3389/fphar.2020.589146", "access": "open", "takeaways": " Ozanimod has been approved for use in the treatment of relapsing forms of multiple sclerosis by the U.S. FDA . The number of new or enlarging T2 lesions over the treatment period decreased in patients treated with ozanimod . No significant difference in causing adverse events between 1 and 0.5 mg was found .", "categories": [ { "category_id": 25, "category_description": "Ozanimod", "category_name": "Ozanimod", "category_slug": "ozanimod", "category_terms": [ "ozanimod", "zeposia" ], "article_count": 29 } ] }, { "article_id": 213, "title": "Poster Abstracts from the 10th International Symposium on Gait and Balance in Multiple Sclerosis: The Role of Fatigue and Fatigability", "summary": "<div><p>Int J MS Care. 2021 Jan-Feb;23(1):45-46. doi: 10.7224/1537-2073-23.1.45. Epub 2021 Feb 23.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33658906/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33658906</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7906032/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7906032</a> | DOI:<a href=\"https://doi.org/10.7224/1537-2073-23.1.45\">10.7224/1537-2073-23.1.45</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33658906/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-01T00:00:00Z", "source": "PubMed", "publisher": "Consortium of Multiple Sclerosis Centers", "container_title": "International Journal of MS Care", "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "the 10th International Symposium", "Gait", "Balance", "Multiple Sclerosis", "The Role", "Fatigue", "Fatigability" ], "doi": "10.7224/1537-2073-23.1.45", "access": "open", "takeaways": "", "categories": [] }, { "article_id": 212, "title": "Editorial", "summary": "<div><p>Int J MS Care. 2021 Jan-Feb;23(1):iv. doi: 10.7224/1537-2073-23.1.iv. Epub 2021 Feb 23.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33658907/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33658907</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7906026/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7906026</a> | DOI:<a href=\"https://doi.org/10.7224/1537-2073-23.1.iv\">10.7224/1537-2073-23.1.iv</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33658907/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-01T00:00:00Z", "source": "PubMed", "publisher": "Consortium of Multiple Sclerosis Centers", "container_title": "International Journal of MS Care", "authors": [ { "author_id": 254660, "given_name": "Francois", "family_name": "Bethoux", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Editorial" ], "doi": "10.7224/1537-2073-23.1.iv", "access": "open", "takeaways": "", "categories": [] }, { "article_id": 201, "title": "Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study", "summary": "<div><p>Neurol Sci. 2021 Mar 3. doi: 10.1007/s10072-021-05145-x. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: So far, a limited number of real-world evidence studies about the effectiveness and safety of alemtuzumab (ALM) have been published, some of them with a relatively small number of included patients. We aimed to study the efficacy and safety of ALM in real-world clinical practice in two MS centers in Slovenia and Croatia.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: This was a retrospective chart review of 71 consecutive patients with relapsing-remitting MS who were treated with ALM from 2015 till 2018. The following data were collected: gender, age at disease onset, disease duration at ALM initiation, previous disease modifying therapy, number of relapses, active MRI lesions, and EDSS in the year prior to ALM initiation and every year of follow-up.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: All patients completed the standard dosing schedule and were followed for a mean time of 3.2±1.1 years after the initiation of treatment. Complete data for the 2 years after treatment (relapses, EDSS, and MRI) were available for 48 patients, of which 14 (29.2%) achieved NEDA. Clinical NEDA was achieved in 38 out of 63 participants (60.3%). In year 1, 24 out of 57 (42.1%) patients achieved NEDA. In year 2, 26 out of 41 (63.4%) patients achieved NEDA. Lower EDSS prior to starting ALM was the only independent predictor of NEDA in a multivariable model. Adverse events occurred in 58 participants (84.1%), with no new safety signals identified.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: According to the data from our cohort of early active RRMS patients we conclude ALM efficacy remains high in the real-world clinical practice.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33660157/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33660157</a> | DOI:<a href=\"https://doi.org/10.1007/s10072-021-05145-x\">10.1007/s10072-021-05145-x</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33660157/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-11T00:00:00Z", "source": "PubMed", "publisher": "Springer Science and Business Media LLC", "container_title": "Neurological Sciences", "authors": [ { "author_id": 214271, "given_name": "Gregor", "family_name": "Brecl Jakob", "ORCID": "http://orcid.org/0000-0003-4998-5974", "country": "SI" }, { "author_id": 240781, "given_name": "Barbara", "family_name": "Barun", "ORCID": null, "country": null }, { "author_id": 203765, "given_name": "Sarah", "family_name": "Gomezelj", "ORCID": "http://orcid.org/0000-0001-8649-5435", "country": null }, { "author_id": 240782, "given_name": "Tereza", "family_name": "Gabelić", "ORCID": null, "country": null }, { "author_id": 240783, "given_name": "Saša", "family_name": "Šega Jazbec", "ORCID": null, "country": null }, { "author_id": 221943, "given_name": "Ivan", "family_name": "Adamec", "ORCID": "http://orcid.org/0000-0003-3873-6526", "country": null }, { "author_id": 240784, "given_name": "Alenka", "family_name": "Horvat Ledinek", "ORCID": null, "country": null }, { "author_id": 324648, "given_name": "Uroš", "family_name": "Rot", "ORCID": "http://orcid.org/0000-0002-2422-8670", "country": null }, { "author_id": 192760, "given_name": "Magdalena", "family_name": "Krbot Skorić", "ORCID": "http://orcid.org/0000-0002-1087-3732", "country": "HR" }, { "author_id": 161545, "given_name": "Mario", "family_name": "Habek", "ORCID": "http://orcid.org/0000-0002-3360-1748", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Effectiveness", "safety", "alemtuzumab", "the treatment", "active relapsing-remitting multiple sclerosis", "a multicenter, observational study" ], "doi": "10.1007/s10072-021-05145-x", "access": "restricted", "takeaways": " A limited number of real-world evidence studies about effectiveness and safety of alemtuzumab (ALM) have been published, some of them with a relatively small number of included patients .", "categories": [ { "category_id": 2, "category_description": "LEMTRADA, or Alemtuzumab, is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.\n\nhttps://www.lemtrada.com/", "category_name": "Alemtuzumab", "category_slug": "alemtuzumab", "category_terms": [ "alemtuzumab", "lemtrada" ], "article_count": 116 } ] }, { "article_id": 202, "title": "Memantine for Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Trials", "summary": "<div><p>Front Neurol. 2021 Feb 15;11:574748. doi: 10.3389/fneur.2020.574748. eCollection 2020.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><b>Background:</b> Multiple sclerosis (MS), a disabling demyelinating disease of the central nervous system, is associated with cognitive impairment, spasticity, and fatigue. There are still no established guidelines on the management of MS-related sequela. Memantine has the potential to reduce glutamate toxicity, thereby reducing consequent cognitive impairment, spasticity, and fatigue. <b>Objectives:</b> This study aims to determine the efficacy and safety of memantine in preventing cognitive impairment, reducing spasticity and fatigue, and controlling disability in MS patients through a review of relevant randomized trials. <b>Methods:</b> MEDLINE, CENTRAL, Scopus, Embase, LILACS, ClinicalTrials.gov, and HERDIN were searched from inception to May 2020 for relevant trials. <b>Results:</b> The search yielded 203 articles; four studies were included in the analysis. Pooled evidence shows that memantine compared with placebo does not significantly improve PASAT, ASS, MFIS, and EDSS scores of patients with MS. Memantine is associated with mild adverse drug events such as dizziness, fatigue, and anxiety. <b>Conclusion:</b> There is not enough evidence to support the efficacy of memantine in preventing cognitive decline, controlling spasticity, reducing fatigue, and preventing disability. Future researches should consider the different MS subtypes, effect of co-administration of disease-modifying therapies, longer duration of administration, and more sensitive outcome measures to evaluate the potential benefit of memantine in MS.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33658967/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33658967</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7917060/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7917060</a> | DOI:<a href=\"https://doi.org/10.3389/fneur.2020.574748\">10.3389/fneur.2020.574748</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33658967/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-02-15T00:00:00Z", "source": "PubMed", "publisher": "Frontiers Media SA", "container_title": "Frontiers in Neurology", "authors": [ { "author_id": 240763, "given_name": "Christian Wilson R.", "family_name": "Turalde", "ORCID": null, "country": null }, { "author_id": 240764, "given_name": "Adrian I.", "family_name": "Espiritu", "ORCID": null, "country": null }, { "author_id": 240765, "given_name": "Veeda Michelle M.", "family_name": "Anlacan", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Memantine", "Multiple Sclerosis", "A Systematic Review", "Meta-Analysis", "Randomized Trials" ], "doi": "10.3389/fneur.2020.574748", "access": "open", "takeaways": " Multiple sclerosis (MS) is a disabling demyelinating disease of the central nervous system . Memantine has the potential to reduce glutamate toxicity, thereby reducing consequent cognitive impairment, spasticity, and fatigue .", "categories": [] }, { "article_id": 200, "title": "Correction for: Signatures of cell stress and altered bioenergetics in skin fibroblasts from patients with multiple sclerosis", "summary": "<div><p>Aging (Albany NY). 2021 Mar 3. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33657013/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210303191644&v=2.14.2\">33657013</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33657013/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-03-03T00:00:00Z", "source": "PubMed", "publisher": "Impact Journals, LLC", "container_title": "Aging", "authors": [ { "author_id": 267640, "given_name": "Jordan M.", "family_name": "Wilkins", "ORCID": null, "country": null }, { "author_id": 267642, "given_name": "Oleksandr", "family_name": "Gakh", "ORCID": null, "country": null }, { "author_id": 267643, "given_name": "Parijat", "family_name": "Kabiraj", "ORCID": null, "country": null }, { "author_id": 267644, "given_name": "Christina B.", "family_name": "McCarthy", "ORCID": null, "country": null }, { "author_id": 245117, "given_name": "W. Oliver", "family_name": "Tobin", "ORCID": null, "country": null }, { "author_id": 177562, "given_name": "Charles L.", "family_name": "Howe", "ORCID": "http://orcid.org/0000-0002-3889-8739", "country": null }, { "author_id": 162720, "given_name": "Claudia F.", "family_name": "Lucchinetti", "ORCID": "http://orcid.org/0000-0001-5070-1196", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T00:16:45Z", "noun_phrases": [ "Correction", "Signatures", "cell stress", "altered bioenergetics", "skin fibroblasts", "patients", "multiple sclerosis" ], "doi": "10.18632/aging.202757", "access": "open", "takeaways": "", "categories": [] }, { "article_id": 195, "title": "Directions for Enhancement of the Therapeutic Efficacy of Mesenchymal Stem Cells in Different Neurodegenerative and Cardiovascular Diseases: Current Status and Future Perspectives", "summary": "<div><p>Curr Stem Cell Res Ther. 2021 Mar 3. doi: 10.2174/1574888X16666210303151237. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Mesenchymal stem cells (MSCs) have shown promising therapeutic effects in a wide variety of medical conditions including neurodegenerative disorders and cardiovascular diseases. Although preliminary research has emphasized the ability of MSCs to engraft at sites of injury, several studies have revealed that MSCs mediate their effects through release of various paracrine factors, and through their antioxidant, anti-inflammatory, immunomodulatory, and anti-apoptotic effects. However, the clinical implications of MSCs application are limited due to their low survival rate in conditions of inflammation, oxidative stress, and nutrient restriction in damaged areas. Furthermore, the function of isolated MSCs is usually affected by the patient's health. Therefore, it is necessary to develop new methods to enhance the therapeutic efficacy of MSCs under pathophysiological conditions. This review provides an overview of the general properties of MSCs, their therapeutic potential in neurodegenerative disorders such as Alzheimer disease, Parkinson disease, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington disease, as well as cardiovascular diseases such as myocardial infarction, diabetic cardiomyopathy, and dilated cardiomyopathy, and their related mechanisms. In addition, this review also discusses potential problems and side effects, as well as current and future directions for improvement of MSCs therapy and their implications and applications.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33655876/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210303135644&v=2.14.2\">33655876</a> | DOI:<a href=\"https://doi.org/10.2174/1574888X16666210303151237\">10.2174/1574888X16666210303151237</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33655876/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-01T00:00:00Z", "source": "PubMed", "publisher": "Bentham Science Publishers Ltd.", "container_title": "Current Stem Cell Research & Therapy", "authors": [ { "author_id": 222325, "given_name": "Lamiaa A.", "family_name": "Ahmed", "ORCID": "http://orcid.org/0000-0003-3476-2815", "country": null }, { "author_id": 305827, "given_name": "Khaled F.", "family_name": "Al-Massri", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-03T18:56:45Z", "noun_phrases": [ "Directions", "Enhancement", "the Therapeutic Efficacy", "Mesenchymal Stem Cells", "Different Neurodegenerative and Cardiovascular Diseases", "Current Status", "Future Perspectives" ], "doi": "10.2174/1574888X16666210303151237", "access": "restricted", "takeaways": " MSCs mediate their effects through release of various paracrine factors, and through their antioxidant, anti-inflammatory, immunomodulatory, and anti-apoptotic effects . Review provides an overview of the general properties of MSC cells, their therapeutic potential in neurodegenerative disorders such as Alzheimer disease, Parkinson disease, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington disease .", "categories": [ { "category_id": 12, "category_description": "Autologous Hematopoietic Stem Cell Transplantation (aHSCT) and other stem cell therapies", "category_name": "Stem Cells", "category_slug": "stem-cells", "category_terms": [ "stem cells", "Autologous hematopoietic stem cell", "ahsct" ], "article_count": 228 } ] }, { "article_id": 194, "title": "What gait features influence the amount and intensity of physical activity in people with multiple sclerosis?", "summary": "<div><p>Medicine (Baltimore). 2021 Mar 5;100(9):e24931. doi: 10.1097/MD.0000000000024931.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Although the mutual relationship between ambulation and physical activity (PA) in people with multiple sclerosis (pwMS) has been described in several studies, there is still a lack of detailed information about the way in which specific aspects of the gait cycle are associated with amount and intensity of PA. This study aimed to verify the existence of possible relationships among PA parameters and the spatio-temporal parameters of gait when both are instrumentally assessed.Thirty-one pwMS (17F, 14 M, mean age 52.5, mean Expanded Disability Status Scale (EDSS) score 3.1) were requested to wear a tri-axial accelerometer 24 hours/day for 7 consecutive days and underwent an instrumental gait analysis, performed using an inertial sensor located on the low back, immediately before the PA assessment period. Main spatio-temporal parameters of gait (i.e., gait speed, stride length, cadence and duration of stance, swing, and double support phase) were extracted by processing trunk accelerations. PA was quantified using average number of daily steps and percentage of time spent at different PA intensity, the latter calculated using cut-point sets previously validated for MS. The existence of possible relationships between PA and gait parameters was assessed using Spearman rank correlation coefficient rho.Gait speed and stride length were the parameters with the highest number of significant correlations with PA features. In particular, they were found moderately to largely correlated with number of daily steps (rho 0.62, P< .001), percentage of sedentary activity (rho = -0.44, P < .001) and percentage of moderate-to-vigorous activity (rho = 0.48, P < .001). Small to moderate significant correlations were observed between PA intensity and duration of stance, swing and double support phases.The data obtained suggest that the most relevant determinants associated with higher and more intense levels of PA in free-living conditions are gait speed and stride length. The simultaneous quantitative assessment of gait parameters and PA levels might represent a useful support for physical therapists in tailoring optimized rehabilitative and training interventions.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33655958/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210303135644&v=2.14.2\">33655958</a> | DOI:<a href=\"https://doi.org/10.1097/MD.0000000000024931\">10.1097/MD.0000000000024931</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33655958/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-03-05T00:00:00Z", "source": "PubMed", "publisher": "Ovid Technologies (Wolters Kluwer Health)", "container_title": "Medicine", "authors": [ { "author_id": 163687, "given_name": "Massimiliano", "family_name": "Pau", "ORCID": "http://orcid.org/0000-0001-9835-3629", "country": "IT" }, { "author_id": 180387, "given_name": "Micaela", "family_name": "Porta", "ORCID": "http://orcid.org/0000-0003-3835-6507", "country": null }, { "author_id": 229606, "given_name": "Giancarlo", "family_name": "Coghe", "ORCID": "http://orcid.org/0000-0002-3796-3279", "country": null }, { "author_id": 148217, "given_name": "Eleonora", "family_name": "Cocco", "ORCID": "http://orcid.org/0000-0002-3878-8820", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-03T18:56:45Z", "noun_phrases": [ "the amount", "intensity", "physical activity", "people", "multiple sclerosis" ], "doi": "10.1097/MD.0000000000024931", "access": "open", "takeaways": " Gait speed and stride length were the parameters with the highest number of significant correlations with PA features . Small to moderate significant correlations were observed between PA intensity and duration of stance, swing and double support phase .", "categories": [] }, { "article_id": 192, "title": "Effects on Motor Control of Personalized Neuromodulation Against Multiple Sclerosis Fatigue", "summary": "<div><p>Brain Topogr. 2021 Mar 3. doi: 10.1007/s10548-021-00820-w. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Fatigue is a hidden symptom of Multiple Sclerosis (MS) disease that nevertheless impacts severely on patients' everyday life. Evidence indicates the involvement of the sensorimotor network and its inter-nodes communication at the basis of this symptom. Two randomized controlled trials (RCTs) showed that the personalized neuromodulation called Fatigue Relief in Multiple Sclerosis (FaReMuS) efficaciously fights multiple sclerosis (MS) fatigue. By this Proof of Concept study, we tested whether FaReMuS reverts the alteration of the brain-muscular synchronization previously observed occurring with fatigue. The cortico muscular coherence (CMC) was studied in 11 patients before and after FaReMuS, a 5-day tDCS (1.5 mA, 15 min per day) anodal over the whole body's somatosensory representation (S1) via a personalized MRI-based electrode (35 cm<sup>2</sup>) against the occipital cathode (70 cm<sup>2</sup>). Before FaReMuS, the CMC was observed at a mean frequency of 31.5 ± 1.6 Hz (gamma-band) and positively correlated with the level of fatigue (p = .027). After FaReMuS, fatigue reduced in average of 28% ± 33% the baseline level, and the CMC frequency reduced to 26.6 ± 1.5 Hz (p = .022), thus forthcoming the physiological beta-band as observed in healthy people. The personalized S1 neuromodulation treatment, ameliorating the central-peripheral communication that subtends simple everyday movements, supports the appropriateness of neuromodulations aiming at increasing the parietal excitability in fighting MS fatigue. The relationship between central-peripheral features and fatigue profile strengthens a central more than peripheral origin of the symptom.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33656622/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210303135644&v=2.14.2\">33656622</a> | DOI:<a href=\"https://doi.org/10.1007/s10548-021-00820-w\">10.1007/s10548-021-00820-w</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33656622/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-05T00:00:00Z", "source": "PubMed", "publisher": "Springer Science and Business Media LLC", "container_title": "Brain Topography", "authors": [ { "author_id": 260623, "given_name": "Matteo", "family_name": "Padalino", "ORCID": null, "country": null }, { "author_id": 260624, "given_name": "Carla", "family_name": "Scardino", "ORCID": null, "country": null }, { "author_id": 260625, "given_name": "Giancarlo", "family_name": "Zito", "ORCID": null, "country": null }, { "author_id": 260626, "given_name": "Andrea", "family_name": "Cancelli", "ORCID": null, "country": null }, { "author_id": 260627, "given_name": "Carlo", "family_name": "Cottone", "ORCID": null, "country": null }, { "author_id": 215052, "given_name": "Massimo", "family_name": "Bertoli", "ORCID": "http://orcid.org/0000-0002-6742-8891", "country": "IT" }, { "author_id": 260628, "given_name": "Eugenia", "family_name": "Gianni", "ORCID": null, "country": null }, { "author_id": 260629, "given_name": "Teresa", "family_name": "L’Abbate", "ORCID": null, "country": null }, { "author_id": 260630, "given_name": "Elisabetta", "family_name": "Trombetta", "ORCID": null, "country": null }, { "author_id": 260631, "given_name": "Camillo", "family_name": "Porcaro", "ORCID": null, "country": null }, { "author_id": 215062, "given_name": "Fabiano", "family_name": "Bini", "ORCID": "http://orcid.org/0000-0002-5641-1189", "country": null }, { "author_id": 260632, "given_name": "Franco", "family_name": "Marinozzi", "ORCID": null, "country": null }, { "author_id": 260633, "given_name": "Maria Maddalena", "family_name": "Filippi", "ORCID": null, "country": null }, { "author_id": 162635, "given_name": "Franca", "family_name": "Tecchio", "ORCID": "http://orcid.org/0000-0002-1325-5059", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-03T18:56:45Z", "noun_phrases": [ "Effects", "Motor Control", "Personalized Neuromodulation", "Multiple Sclerosis Fatigue" ], "doi": "10.1007/s10548-021-00820-w", "access": "restricted", "takeaways": " Fatigue Relief in Multiple Sclerosis (FaReMuS) efficaciously fights multiple sclerosis fatigue . Brain Topogr. 2021 Mar 3.", "categories": [ { "category_id": 18, "category_description": "Search terms: telerehabilitation, physical therapy, virtual reality, gamification, neurostimulation, cognitive training, spasticity, motor control.\n\nSuggested by Alejandro Carrabs", "category_name": "Physical therapy and Telerehabilitation", "category_slug": "physical-therapy-and-telerehabilitation", "category_terms": [ "telerehabilitation", "physical therapy", "virtual reality", "gamification", "neurostimulation", "cognitive training", "spasticity", "motor control" ], "article_count": 177 } ] } ] }